keyword
MENU ▼
Read by QxMD icon Read
search

Mronj

keyword
https://www.readbyqxmd.com/read/28101496/medication-related-osteonecrosis-of-the-jaw-a-preliminary-retrospective-study-of-130-patients-with-multiple-myeloma
#1
Woo-Sung Choi, Jae-Il Lee, Hyun-Joong Yoon, Chang-Ki Min, Sang-Hwa Lee
BACKGROUND: Multiple myeloma (MM) is characterized by a neoplastic proliferation of plasma cells primarily in the bone marrow. Bisphosphonates (BP) are used as supportive therapy in the management of MM. This study aimed to analyze the incidence, risk factors, and clinical outcomes of medication-related necrosis of the jaw (MRONJ) in MM patients. METHODS: One hundred thirty MM patients who had previous dental evaluations were retrospectively reviewed. Based on several findings, we applied the staging and treatment strategies on MRONJ...
December 2017: Maxillofacial Plastic and Reconstructive Surgery
https://www.readbyqxmd.com/read/28087282/short-term-perioperative-teriparatide-therapy-for-the-prevention-of-medication-related-osteonecrosis-of-the-jaw-a-randomized-controlled-preclinical-study-in-rats
#2
Mohammad Zandi, Arash Dehghan, Amirhossein Mohammadi-Mofrad, Payam Amini, Farshid Vahdatinia
OBJECTIVE: Dentoalveolar procedures in patients receiving bisphosphonates and other antiresorptive agents are associated with an increased risk of medication-related osteonecrosis of the jaw (MRONJ). The aim of present study was to evaluate the effects of perioperative teriparatide (TPD) therapy in prevention of MRONJ. SUBJECTS AND METHODS: Two protocols of TPD therapy were studied. For protocol A, 25 TPD-treated (AT) and 25 control (AC) rats received 5 weekly injection of 0...
December 19, 2016: Journal of Cranio-maxillo-facial Surgery
https://www.readbyqxmd.com/read/28078129/osteonecrosis-of-the-jaw-associated-with-ziv-aflibercept
#3
Hani Mawardi, Peter Enzinger, Nadine McCleary, Reshma Manon, Alessandro Villa, Nathaniel Treister, Sook-Bin Woo
Medication-related osteonecrosis of the jaw (MRONJ) has been associated with medications that include bisphosphonates (BPs), denosumab, bevacizumab and sunitinib. Ziv-aflibercept is a recombinant human vascular endothelial growth factor (VEGF) receptor which has been used to treat patients with various advanced solid tumors. We report three patients without a history of the use of medications known to cause MRONJ presenting with jaw osteonecrosis typical for MRONJ following therapy with ziv-aflibercept. All patients had metastatic gastrointestinal cancer treated with ziv-aflibercept and were evaluated for MRONJ because of exposed bone in the oral cavity...
December 2016: Journal of Gastrointestinal Oncology
https://www.readbyqxmd.com/read/28061356/clinical-differences-in-autofluorescence-between-viable-and-nonvital-bone-a-case-report-with-histopathologic-evaluation-performed-on-medication-related-osteonecrosis-of-the-jaws
#4
Ilaria Giovannacci, Marco Meleti, Domenico Corradi, Paolo Vescovi
Medication-related osteonecrosis of the jaws (MRONJ) is an adverse side effect of several drug therapies, including bisphosphonates (BPs). Osteonecrosis of the jaw specifically related to BP therapy is usually referred to using the acronym BRONJ. However, no consensus has yet been reached regarding the most appropriate management of BRONJ. The greatest success rates have been recorded with surgical removal of necrotic bone. In particular, erbium:yttrium-aluminum-garnet (Er:YAG) laser-assisted surgery has shown significantly better results than conventional surgical approaches...
December 15, 2016: Journal of Oral and Maxillofacial Surgery
https://www.readbyqxmd.com/read/28042979/does-the-addition-of-bone-morphogenetic-protein-2-to-platelet-rich-fibrin-improve-healing-after-treatment-for-medication-related-osteonecrosis-of-the-jaw
#5
Jung-Hyun Park, Jin-Woo Kim, Sun-Jong Kim
PURPOSE: To investigate the effect of the addition of bone morphogenetic protein 2 (BMP-2) to leukocyte-rich and platelet-rich fibrin (L-PRF) on the treatment of medication-related osteonecrosis of the jaws (MRONJ), this study compared the healing outcome of combined use of BMP-2 and L-PRF with single use of L-PRF. PATIENTS AND METHODS: Of 55 patients who were diagnosed with MRONJ, 25 were treated with L-PRF alone and 30 were treated with L-PRF and recombinant human BMP-2...
December 11, 2016: Journal of Oral and Maxillofacial Surgery
https://www.readbyqxmd.com/read/28034471/pentoxifylline-a-review-of-its-use-in-osteoradionecrosis
#6
REVIEW
A J Lyons, P A Brennan
Pentoxifylline has been used to treat complications related to fibrosis for over 20 years. Formerly used to treat those after radiotherapy such as osteoradionecrosis (ORN), it is now being tried for medication-related osteonecrosis of the jaw (MRONJ), which can occur after prolonged use of bisphosphonates. We review theories on the formation of fibrosis in patients with ORN, discuss the pharmacology of pentoxifylline and vitamin E, and report published outcomes. To our knowledge no prospective randomised controlled trial has investigated the benefits of these agents in cases of ORN, but reported outcomes in many published case series are encouraging...
December 26, 2016: British Journal of Oral & Maxillofacial Surgery
https://www.readbyqxmd.com/read/27924427/treatment-of-medication-related-osteonecrosis-of-the-jaws-mronj-with-ultrasonic-piezoelectric-bone-surgery-a-case-series-of-20-treated-sites
#7
Cornelio Blus, Giulio Giannelli, Serge Szmukler-Moncler, Germano Orru
PURPOSE: There is no consensus on how to successfully treat medication-related osteonecrosis of the jaws (MRONJ). We report here on the application of piezoelectric bone surgery to treat MRONJ in combination with antibiotherapy and on its possible benefit. MATERIEL AND METHODS: A cohort of 18 consecutive patients has been treated for MRONJ; they involved 20 sites, 15 in the mandible, and five in the maxilla. Surgical removal of the necrotic areas and debridement was performed with a powerful piezoelectric surgery device (max 90 W) in combination with antibiotherapy...
December 6, 2016: Oral and Maxillofacial Surgery
https://www.readbyqxmd.com/read/27856150/comparison-of-auto-fluorescence-and-tetracycline-fluorescence-for-guided-bone-surgery-of-medication-related-osteonecrosis-of-the-jaw-a-randomized-controlled-feasibility-study
#8
O Ristow, S Otto, C Geiß, V Kehl, M Berger, M Troeltzsch, S Koerdt, B Hohlweg-Majert, C Freudlsperger, C Pautke
Recent studies have indicated that bone shows auto-fluorescence under an appropriate fluorescence lamp. The aim of this preliminary study was to compare the success rates of the established tetracycline fluorescence-guided bone surgery with auto-fluorescence-guided bone surgery in the treatment of medication-related osteonecrosis of the jaw (MRONJ). Forty patients suffering from MRONJ were referred for surgical treatment and were divided randomly into two groups: auto-fluorescence (n=20) or tetracycline fluorescence (n=20) guided bone surgery...
February 2017: International Journal of Oral and Maxillofacial Surgery
https://www.readbyqxmd.com/read/27843453/medication-related-osteonecrosis-of-the-jaws-considerations-on-a-new-antiresorptive-therapy-denosumab-and-treatment-outcome-after-a-13-year-experience
#9
Gianfranco Favia, Angela Tempesta, Luisa Limongelli, Vito Crincoli, Eugenio Maiorano
Medication-related osteonecrosis of the jaw (MRONJ) is a serious complication in patients receiving antiresorptive therapies for bone neoplastic localizations and osteoporosis. The aim of this study was to evaluate the clinicopathological features of MRONJ in a cohort of patients treated by new antiresorptive drugs (denosumab) and the corresponding outcome after 13-year maximum follow-up. Overall, 244 patients affected by MRONJ were treated from 2003 to 2015. After clinical and radiological examinations, all lesions were staged according to a dimensional staging system and then surgically treated...
2016: International Journal of Dentistry
https://www.readbyqxmd.com/read/27837344/platelet-rich-fibrin-may-reduce-the-risk-of-delayed-recovery-in-tooth-extracted-patients-undergoing-oral-bisphosphonate-therapy-a-trial-study
#10
Takuya Asaka, Noritaka Ohga, Yutaka Yamazaki, Jun Sato, Chiharu Satoh, Yoshimasa Kitagawa
OBJECTIVES: The aim of the present study was to evaluate the effectiveness of platelet-rich fibrin (PRF) as a wound-healing accelerator in patients undergoing oral bisphosphonate therapy and requiring tooth extractions. MATERIALS AND METHODS: A total of 102 patients were divided into a PRF group and control group. The patients received oral bisphosphonate therapy for osteoporosis for an average of 32 months. Blood was collected and PRF was introduced into the socket of the PRF group only...
November 11, 2016: Clinical Oral Investigations
https://www.readbyqxmd.com/read/27836551/clinical-features-of-peri-implant-medication-related-osteonecrosis-of-the-jaw-is-there-an-association-to-peri-implantitis
#11
Matthias Troeltzsch, David Cagna, Philip Stähler, Florian Probst, Gabriele Kaeppler, Markus Troeltzsch, Michael Ehrenfeld, Sven Otto
The purpose of this study was to examine the behavior of dental implants in patients diagnosed with MRONJ and to analyze the characteristics of peri-implant MRONJ. It was hypothesized that peri-implant parameters are not associated with peri-implant MRONJ. A retrospective study design was selected to address the research purpose. Patients with confirmed MRONJ and the simultaneous presence of dental implants who presented between 2010 and 2016 served as the study cohort. Predefined inclusion and exclusion criteria were applied...
December 2016: Journal of Cranio-maxillo-facial Surgery
https://www.readbyqxmd.com/read/27796573/secretomes-from-mesenchymal-stem-cells-participate-in-the-regulation-of-osteoclastogenesis-in-vitro
#12
Kenichi Ogata, Wataru Katagiri, Hideharu Hibi
OBJECTIVES: The receptor activator of nuclear factor kappa-B ligand (RANKL) inhibitors are novel clinically effective agents that inhibit osteoclast differentiation, function, and survival by binding to RANKL. Medication-related osteonecrosis of the jaw (MRONJ), caused as a result of treatment using denosumab, is a newly emerging type of bone necrosis, the exact pathogenesis of which is unknown. Several studies recently showed that the intravenous administration of mesenchymal stem cells (MSCs) improved the osteonecrosis of the jaw, and it was hypothesized that paracrine effects by secretomes from MSCs are the main constituent...
October 29, 2016: Clinical Oral Investigations
https://www.readbyqxmd.com/read/27780611/experimental-model-of-osteonecrosis-of-the-jaw-in-rats-treated-with-zoledronic-acid
#13
M E Kolpakova, A A Zubarevа, T D Artamonova, E K Lisovskaya, S G Chefu, O D Yagmurov, A I Yaremenko, T D Vlasov
We have examined the development of medication-related osteonecrosis of the jaws (MRONJ) in rats with no previous accumulation of zoledronic acid in the mandible. Ten male Wistar rats (weight 350-400g) were anaesthetised with chloral hydrate 450mg/kg intraperitoneally and the first and second mandibular molars on the left side were extracted. The five experimental rats were given six injections of zoledronic acid 0.18mg/kg over the next four weeks (total dose 1.08mg/kg). Two injections were given at once as an intravenous bolus injection (0...
October 22, 2016: British Journal of Oral & Maxillofacial Surgery
https://www.readbyqxmd.com/read/27771829/a-retrospective-study-of-osteomyelitis-and-osteonecrosis-of-the-jaws-and-its-etiologic-implication-of-bisphosphonate-in-asians
#14
Sung Ok Hong, Chae-Yoon Lee, Junho Jung, Deog-Yoon Kim, Christian Walter, Yong-Dae Kwon
OBJECTIVE: The objective of this study were to find the annual case trend of inflammatory jawbone diseases and to investigate the impact of medication-related osteonecrosis of the jaws (MRONJ). MATERIAL AND METHODS: A retrospective study of 372 patients diagnosed with inflammatory jawbone condition except for alveolar osteitis from 2007 to 2015 was initiated. History taking and investigation of etiologic factors MRONJ, osteoradionecrosis (ORN), odontogenic infection, foreign body, and trauma were investigated...
October 22, 2016: Clinical Oral Investigations
https://www.readbyqxmd.com/read/27771152/grade-of-sclerosis-in-the-contralateral-mandibular-area-in-osteonecrosis-of-the-jaws
#15
L Bagan, M Leopoldo-Rodado, R Poveda-Roda, J Murillo-Cortes, J M Diaz-Fernández, J Bagan
The objective of this study was to compare the grade of radiographic sclerosis between the area of osteonecrosis and the at-risk contralateral mandibular area without osteonecrosis. Three groups were studied: group 1 comprised 30 cases of medication-related osteonecrosis of the jaws (MRONJ); group 2 was the healthy contralateral area without osteonecrosis of the group 1 cases; group 3 comprised 30 healthy controls. ImageJ software was used to analyze the computed tomography images, and the grade of bone sclerosis was compared between the three groups...
February 2017: International Journal of Oral and Maxillofacial Surgery
https://www.readbyqxmd.com/read/27741546/bisphosphonate-and-medication-related-osteonecrosis-of-the-jaw-a-review
#16
Thomas Mücke, Christian R Krestan, David A Mitchell, Jan S Kirschke, Arno Wutzl
For patients with malignant disease taking bisphosphonates and denosumab, the incidence of medication-related osteonecrosis of the jaw (MRONJ) is up to 15% in contrast to 0.01% in patients with osteoporosis. Clinical presentation of MRONJ extends from asymptomatic exposure of bone in 94% of patients to severe cases of mandibular fractures in a minority of 4.5%. The strongest risk factors for MRONJ are invasive dental procedures and dental infections. Advances in imaging provide more preoperation information compared with panoramic radiograph...
July 2016: Seminars in Musculoskeletal Radiology
https://www.readbyqxmd.com/read/27721837/medication-related-osteonecrosis-of-the-jaw-new-insights-into-molecular-mechanisms-and-cellular-therapeutic-approaches
#17
Thomas Lombard, Virginie Neirinckx, Bernard Rogister, Yves Gilon, Sabine Wislet
In recent years, medication-related osteonecrosis of the jaw (MRONJ) became an arising disease due to the important antiresorptive drug prescriptions to treat oncologic and osteoporotic patients, as well as the use of new antiangiogenic drugs such as VEGF antagonist. So far, MRONJ physiopathogenesis still remains unclear. Aiming to better understand MRONJ physiopathology, the first objective of this review would be to highlight major molecular mechanisms that are known to be involved in bone formation and remodeling...
2016: Stem Cells International
https://www.readbyqxmd.com/read/27720716/possible-pathogenic-engagement-of-soluble-semaphorin-4d-produced-by-%C3%AE-%C3%AE-t-cells-in-medication-related-osteonecrosis-of-the-jaw-mronj
#18
Alexandru Movila, Hani Mawardi, Kazuaki Nishimura, Tomomi Kiyama, Kenji Egashira, Jae-Young Kim, Alessandro Villa, Hajime Sasaki, Sook-Bin Woo, Toshihisa Kawai
Prior consensus held that medication-related osteonecrosis of the jaw (MRONJ) lesion was composed of necrotic bone; however, more recent studies have identified inflammatory infiltrates in the lesion. Herein, we report that remarkably elevated infiltrating γδT cells (90% of lymphocytes) express Semaphorin 4D (Sema4D) in human patient with MRONJ lesion, whereas γδT cells only account for 2-5% of lymphocytes in blood. Importantly, Sema4D is implicated in the pathogenesis of T cell-mediated inflammatory diseases, such as rheumatoid arthritis and multiple sclerosis...
November 4, 2016: Biochemical and Biophysical Research Communications
https://www.readbyqxmd.com/read/27668100/medication-related-osteonecrosis-of-jaws-a-low-level-laser-therapy-and-antimicrobial-photodynamic-therapy-case-approach
#19
Mariana Comparotto Minamisako, Guilherme Henrique Ribeiro, Mariáh Luz Lisboa, Mabel Mariela Rodríguez Cordeiro, Liliane Janete Grando
Medication-related osteonecrosis of the jaws (MRONJ) can be considered an inability of the alveolar bone to respond to an injury, which frequently leads to severe local and systemic complications. Once the problem is installed, dentist must use all therapeutic approaches recommended. This manuscript reports a successful management of MRONJ handled with antibiotics, conservative debridement, low-level laser therapy (LLLT), and photodynamic therapy (PDT) up to 12 months. As healing of MRONJ may be very slow, combined therapeutic approaches are required...
2016: Case Reports in Dentistry
https://www.readbyqxmd.com/read/27659614/pharmaceuticals-mronj-and-prostheses
#20
H Crane, V Toedtling
No abstract text is available yet for this article.
September 23, 2016: British Dental Journal
keyword
keyword
41952
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"